The Sunshine Reporter

The leading companies in the Biologics Market include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc, Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc, Biogen., bluebird bio, Inc, Janssen Global Services, LLC, Cellitron Group and others.

DelveInsight’s “Biologics Market” research report provides the current and forecasted Biologics market size, share, and trends analysis for the next five years, upcoming innovations in the segment, and major market drivers & barriers. The report also covers the key competitors and emerging devices in the domain.

Biologics Market – Key Takeaways 

• The rising prevalence of autoimmune disorders such as rheumatoid arthritis is one of the main drivers of the biologics market. Another key factor responsible for the growth of the biologics market is the increasing prevalence of genetic disorders. 
• Some of the key factors, such as the challenging manufacturing processes, high cost of biologics, and availability of biosimilars, are expected to hamper the biologics market growth.
• As per the assessment, in the product type segment of the biologics market, the monoclonal antibodies category is estimated to generate significant revenue during the forecast period owing to their specific features. Monoclonal antibodies are considered highly specific, resulting in fewer side effects in patients. 
• According to DelveInsight’s analysis, among all the regions, North America is expected to account for the largest share of the global biologic drugs market. This can be ascribed to the high focus on therapy development for rare diseases with orphan designations, the rising prevalence of cancers, a supportive regulatory environment, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments.

Biologics Market – Key Developments and Breakthroughs

Over the years, the Biologics market has evolved significantly owing to the active participation of global companies and technological advancements in the domain. Some of the major advancements in recent years in the Biologics market are –

• On March 07, 2023, Mesoblast Limited (Nasdaq: MESO; ASX: MSB) announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the Company’s Biologics License Application (BLA) resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA considers the resubmission a complete response and has set a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2023.
• On March 05, 2023, Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted Eisai’s supplemental Biologics License Application (sBLA) for LEQEMBI™ (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application but has not yet publicly announced the date of the meeting.
• On October 15, 2021, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
• In August 2021, Bristol Myers Squibb received conditional marketing authorization for Abecma (idecabtagene vicleucel) from the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy.
• In June 2021, the US FDA approved the product approval to Biogen Inc’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease in an accelerated approval pathway.

As per DelveInsight, the ongoing clinical & commercial development activities and research in the domain will contribute immensely to the Biologics Market growth in the coming years.

Key Companies in the Biologics Market

The leading companies in the Biologics market include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc, Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc, Biogen., bluebird bio, Inc, Janssen Global Services, LLC, Cellitron Group and others.

As per DelveInsight, several new players are expected to enter the Biologics market in the coming years due to the high growth rate and positive return. The entry of new players and the launch of emerging products will immensely drive market growth.

Learn How New Players’ Entries Will Transform the Biologics Market Dynamics in the Coming Years @ 

https://www.delveinsight.com/sample-request/biologics-market

Scope of the Biologics Market Report:

• Study Period – 2019-2027
• Geography Covered – Global (North America, Europe, Asia-Pacific, and the Rest of the World)
• Biologics Market by Product Type – Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Proteins, and Others
• Biologics Market By Application – Oncology, Immunology, Infectious Diseases, Neurological Diseases, and Others
• Biologics Market By Manufacturing Type – In-House and Outsourced
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

DelveInsights’ Remark: The “Biologics Market” is anticipated to grow at a significant CAGR of 9.59% till 2027. North America is expected to dominate the Global Biologics Market.

Learn More About Key Trends and Developments in the Biologics Market @ 

https://www.delveinsight.com/sample-request/biologics-market

Table of Content

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Biologics Market Key factors analysis

5. Biologics Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Biologics Market

7. Biologics Market Layout

8. Biologics Global Company Share Analysis

9. Biologics Product Profiles and Key Companies

10. Project Approach

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

*The Table of Contents (TOC) is not exhaustive. Refer to the sample report for the complete TOC. The final TOC may vary as per the customization and requirements.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/biologics-market

Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/